C4 Therapeutics Inc (CCCC) is a Healthcare · Biotechnology company listed on NASDAQ. Price $3.44 (+0.73%), Market cap $0.39B, 52-week low–high $1.25 ~ $3.68.
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaboration
Financial statements, price targets, institutional (13F) holdings and related news for C4 Therapeutics Inc are updated in real time on BlackAll Trade.
C4 Therapeutics Inc trades at $3.44 (+0.73%). Real-time quotes and charts are available on BlackAll Trade.
C4 Therapeutics Inc has a market cap of about $0.39B.
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioav